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Abstract
Background: This study aims to validate and evaluate the psychometric properties and reliability of the Italian
version of the Expanded Prostate Cancer Index Composite – Short Form (EPIC-26), a measure of quality of life (QoL)
for prostate cancer patients.
Methods: Two hundred and eighty-four prostate cancer patients completed the Italian version of the EPIC-26
questionnaire at 45 days (T1) and 3 months (T2) after robot-assisted radical prostatectomy (RARP). Psychometric
properties were evaluated using structural equation modeling: the goodness of fit of the correlated five-factor
model (CFFM) for the EPIC-26 was assessed using the confirmatory factor analysis (CFA), while longitudinal
invariance was conducted to assess the ability of the EPIC-26 to measure QoL construct over time. Test-retest
reliability was assessed as well by considering intraclass correlations.
Results: At T1, the CFFM model displayed a good fit to data. Similarly, the model showed an adequate fit also at
T2. Results of the reliability analysis attested the acceptable internal consistency and test-retest reliability of each
dimension: all Cronbach’s alphas could be classified as acceptable (i.e., above .65) except for low Cronbach’s alpha
for hormonal dysfunction at T1 (i.e., .638) and urinary irritation at both waves. (i.e., respectively .585 and .518). Finally,
psychometric properties were invariant over time and each of the five dimensions of QoL displayed from moderate
(all ICCs above .500) to good test-retest reliability (i.e. ICC for urinary incontinence = .764).
Conclusions: Results of the CFA and the measurement invariance analysis demonstrated the validity of the Italian
version of the EPIC-26 to assess QoL in prostate cancer patients. Its reliability and good psychometric qualities are
well-supported, thus providing a valid tool to assess health-related quality of life and its change over time in
prostate cancer patients.
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Background
Prostate cancer is one of the most common cancers in
men with almost 70% of the cases occurring in the
developed countries, where advances in screening and
treatments have led to an increase in early tumor detec-
tion and a prolonged patient lifespan [1, 2]. Despite
these advances, prostate cancer patients report a worsen-
ing of their quality of life (QoL) [3–5]. Indeed, radiother-
apy and invasive surgery can cause urinary incontinence,
sexual problems and bowel dysfunction, and they are
often related to distress, anxiety or fatigue [6–9]. In this
vein, patient-reported outcomes (PROs) play an import-
ant role in the process of care of prostate cancer patients
who have to deal with both functional and psychological
problems [5, 7, 8]. A recent systematic review showed
that, among the great availability of prostate-cancer spe-
cific questionnaires measuring PROs, the Expanded
Prostate Cancer Index Composite (EPIC) is the most
suitable cancer-specific survey in urology departments to
measure patient’s physical and psychological well-being
[10]. Through the “Evaluating Measures of Patient-Re-
ported Outcomes” (EMPRO) tool, the EPIC obtained,
along with the University of California Los Angeles-
Prostate Cancer Index (UCLA-PCI), the highest score in
terms of concepts and population intended to assess,
and very high scores in validity, interpretability, and re-
sponsiveness. Moreover, EPIC was also recommended
because it is the only questionnaire investigating hormo-
nal and irritative/incontinence urinary dysfunction
domains. The original version of EPIC is composed of
50 items and is developed by Wei and colleagues [11].
Considering the difficulty of administering the question-
naire during clinical practice, a short-version was intro-
duced composed of 26 items. The new version, named
EPIC-26, is the most used brief self-report scale and it
has already been validated in Norway, USA, China and
Germany [12–15].
Its administration allows physical and psychological
information to be collected on specific dimensions, as
urinary incontinence, urinary irritation, bowel, sexual
and hormonal dysfunction, scored from 0 (worst) to 4 or
5 (best). All domains of EPIC-26 are highly correlated
with all domains of the longer version EPIC-50 (r ≥ 0.96)
[12–15].
The proposed factor structure for the EPIC-26 is a
correlated five-factor model (CFFM) [15, 16]. As shown
in Fig. 1, urinary incontinence and urinary irritation are
both measured by four items; bowel and sexual dysfunc-
tions are both measured by six items, while five items
measure hormonal dysfunction. A single item (i.e., item
9) measuring overall urinary symptomatology is a stand-
alone item and is not included in any of the domains be-
cause it overlaps on both urinary incontinence and urin-
ary irritation.
High internal consistency and test-retest reliability -
Cronbach’s alpha ≥0.70 and r ≥ 0.69 respectively - have
been reported in all the domains [15–17]. These psycho-
metric properties, along with being less time-consuming
and easier to use than the full version, encouraged the use
of the EPIC-26 in clinical and research setting over time.
Considering the pivotal role of the EPIC-26 to assess
QoL in prostate cancer patients [10], the main aim of
this study was to develop an Italian version of this self-
report measure and to evaluate its psychometric proper-
ties in term of dimensionality, longitudinal invariance,




An Italian sample of 284 patients with localized prostate
cancer who had undergone RARP were recruited at the
European Institute of Oncology in Milan between July
2015 and July 2016. Patients were included in the study
if they: 1) were diagnosed with localized prostate cancer,
2) were native Italian speakers, 3) referred to the Value
Based Project and 4) had neither neurological nor
psychopathological problems. They completed the ques-
tionnaire 45 days (T1) and 6months (T2) after RARP
surgery. Informed consent was provided and signed by
each participant. The participation in the study was vol-
untary and at each moment, patients could withdraw
their consent. The study was developed in accordance
with the principles stated in the Declaration of Helsinki
(59th WMA General Assembly, Seoul, 2008) and was
approved by the Ethical Committee of the European
Institute of Oncology.
Language equivalence
Transcultural adaptation of the EPIC-26 survey in Italian
was done using forward and backward translation by
two experts [18]. One English native speaker translated
the original English EPIC-26 version into Italian. Then,
two expert psychologists assessed the consistency of the
translation and approved the first version of the Italian
EPIC-26. This version was pretested in a cognitive
debriefing study with ten prostate cancer patients in
order to assess its readability, understand ability, and
comprehensibility. The cognitive debriefing was con-
ducted by a psychologist. The time taken by each patient
to complete the EPIC-26 was recorded. Patients then
completed a cognitive debriefing task in which they
asked about the clarity of the instructions and items, and
the level of ease of response to each item.
Instructions (M = 4.80, ds = 0.632) and items (M =
4.96, ds = 0.08) were rated as clear on a five-point Likert
scale (ranging from 1 = not at all to 5 = completely).
Items were also rated as easy to complete (M = 4.96, ds =
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0.07) on a five-point Likert scale (from 1 = not at all to
5 = completely). Only two patients asked for further in-
formation about the “13.b” item (“breast tenderness/en-
largement”): they did not understand the meaning of the
question and asked for more information. They did not
know this side effect and were not able to visualise it as
a possible consequence of the disease. Then, a second
mother tongue speaker translated this version back into
English language. The results of this back translation
were virtually identical to the original English version.
Fig. 1 The correlated five-factor model. Note: IN = Urinary incontinence; IR = Urinary irritation; BD = Bowel dysfunction; SD = Sexual dysfunction;
HD = Hormonal dysfunction
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Statistical analysis
The psychometric properties were assessed using struc-
tural equation modelling in a sample of patients who
had undergone Robot-Assisted Radical Prostatectomy
(RARP). Specifically, we aimed at assessing the goodness
of fit of the CFFM for the EPIC-26 using confirmatory
factor analysis (CFA) and testing reliability. Then, longi-
tudinal invariance was assessed to evaluate the ability of
the EPIC-26 to reliably and validly measure its relevant
constructs over time. Longitudinal invariance is a neces-
sary requisite to assess stability and change of constructs
over time since without invariance it is not possible to
distinguish between true changes in outcomes over time
and differences in the psychometric properties of the
instrument.CFA with robust maximum likelihood (MLR)
[19] was performed with Mplus 8.2 to evaluate the
CFFM of the EPIC-26 separately at T1 and T2. Overall
goodness-of-fit of the proposed models was evaluated
assessing multiple indices of fit: the chi square test (Χ2),
the root mean square error of approximation (RMSEA),
the comparative fit index (CFI), the Tucker-Lewis index
(TLI), and the standardized root mean square residual
(SRMR). The model fit was firstly evaluated using the Χ2
statistic. However, because of its sensitivity to the sample
size, other indices were also used [20]. Specifically,
values above .90 for the CFI and TLI, a RMSEA below
.06, and a SRMR below .08 indicate a good fitting model.
The assessment of longitudinal invariance is a sequential
process with seven specific steps. As reported in Table 1,
configural, metric, scalar, and residual variances invari-
ances were sequentially performed and followed by
invariance of the latent factor variances, covariances, and
means. The main assumption of configural invariance is
that the same factor structure will hold in the two waves.
Metric and scalar invariance respectively assume that
factor loadings and item intercepts are equivalent across
time. The assumption of residual invariance is that the
residual variances of items are equivalent across time.
Equality of residual variances implies equal reliability
over time. Finally, the invariance of factor variances, co-
variances, and means assume respectively that latent fac-
tor variances, invariances, and means are equal across
the two waves. The difference in CFI (i.e., ΔCFI) be-
tween a model and the subsequent level of invariance
was considered to evaluate whether the hypothesis of in-
variance should be retained. Measurement invariance is
indicated by a ΔCFI less than or equal to −.010 [21].
When invariance was not found, we tested partial invari-
ance by checking modification index (MI). At each step,
we identified all the non-invariant parameters by review-
ing MI and then freely estimated these parameters
across time. Analyses were performed using the full-in-
formation maximum likelihood estimator, which allows
for inclusion of cases with partially missing data.
Internal consistency was assessed by computing
respectively Cronbach’s alpha of each dimension in the
two waves. Test-retest reliability was computed by con-
sidering intraclass correlations (ICCs). Specifically, ICCs
(and their 95% confidence interval) were used to exam-
ine correlations between repeated measurements of each
QoL dimensions obtained from the same patient at dif-
ferent times (i.e., T1 and T2). We used ICC Model 3
(i.e., two-way mixed effects, absolute agreement, single
measure/rater) to quantify test-retest reliability [22, 23].
ICC values below 0.50 were considered to indicate poor
reliability, from 0.50 to 0.75 moderate, from 0.75 to 0.90
good, and above 0.90 excellent reliability [24].
Results
As shown in Table 2, participants had a median age of
63.4 ± 7.12 and a BMI of 26.6 ± 3.54. Two hundred and
thirty-three men underwent radical prostatectomy with
nerve-sparing (NS) surgical procedure (N = 159 with bi-
lateral NS; N = 75 with unilateral NS), while the other
17.6% (50/284) of the sample undergone surgery without
NS. The distribution of item responses was reported in
Table 3.
At T1, the CFFM model displayed a good fit to data
[SB Χ2 (265) = 553.092, p = .000; RMSEA = .055; CFI =
.921; TLI = .911; SRMR = .067]. Similarly, the model
showed an adequate fit also at T2 [SB Χ2 (265) =
605.020, p = .000; RMSEA = .060; CFI = .907; TLI = .894;
SRMR = .061]. Specifically, all standardized factor load-
ings except the ones for items 13 and 23 are significant
at T1. At T2, all standardized factor loadings are signifi-
cant except the ones for items 7, 12, and 13.
Table 4 summarizes the sequential process of assessing
measurement invariance by reporting fit indices of each
model and the ΔCFI between them. In the first step, con-
figural invariance was assessed. Specifically, fit indices




The factor structure is the same across waves
B Metric model A + all factor loadings are constrained to be
equivalent across waves




C + all residual variances of items are
constrained to be equivalent across waves
E Factor variances
model
D + all latent factor variances are constrained




E + all covariances among latent factors are
constrained to be equivalent across waves
G Factor means
model
F + all latent factor means are constrained to
be equivalent across waves
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attested that the CFFM had a good fit in both waves hold
in the two waves [SB Χ2 (1105) = 1892.249, p = .000;
RMSEA = .044; CFI = .913; TLI = .904; SRMR= .062].
Equivalence of the factor loading across waves was then
examined in the metric invariance model. This model did
not fit significantly worse than the configural model
(ΔCFI = −.010) thus indicating that each item was related
to the latent factor equivalently across waves. The scalar
invariance model fitted significantly worse than the metric
invariance one (ΔCFI = −.028). Subsequently, the MIs sug-
gested that the intercept of items 14, 5, 25, 6 and 21 were
the main sources of significant misfit and should be freely
estimated across waves. After doing this, the partial scalar
invariance model did not fit significantly worse than the
metric invariance one (ΔCFI = −.009) and thus denoting
that T1 and T2 had the same expected response for each
item except for items 14, 5, 25, 6, and 21 at the same abso-
lute level of the traits being measured. The residual vari-
ances invariance model fitted significantly worse than the
partial scalar one (ΔCFI = −.012). The MIs suggested that
the residual variances of items 13 and 22 should be freely
estimated across the two waves. After doing so, the partial
residual variances invariance model did not significantly
fit worse than the previous invariance model (ΔCFI =
−.005) and thus denoting that the amount of item variance
not accounted by the latent factor was the same across the
two waves except for items 13 and 22. After reaching par-
tial measurement invariance, structural invariance was
assessed by evaluating factor variances, factor covariances,
and factor means invariance. The factor variance model
did not fit significantly worse than the partial residual vari-
ances invariance model (ΔCFI = −.002) thus indicating
equivalent variances or namely equal amounts of individ-
ual differences in QoL across the two waves. Results dem-
onstrated the equivalence of relationships among the five
latent factors across waves as indicated by a no significant
decrease of model fit between the factor covariances in-
variance model and the previous model (ΔCFI = −.004).
Finally, the factor means invariance model fitted signifi-
cantly worse than the factor covariances model (ΔCFI =
−.036). The MIs suggested that the means of the latent
factors of urinary incontinence and urinary irritation
should be freely estimated across the two waves. After
doing so, the partial factor means invariance model did
not significantly fit worse than the previous invariance
model (ΔCFI = −.006) and thus denoting that only these
two factors means were significantly different and decreas-
ing over time.
This final model showed an adequate fit to data [SB
Χ2 (1176) = 2291.617, p = .000; RMSEA = .051; CFI =
.877; TLI = .872; SRMR = .078]. Standardized parameters
of this model are reported in Fig. 2. All the standardized
factor loadings are significant and above .30 in absolute
value with the exception of items 5, 6, 12, 13, 22, and 23.
Intercepts of items 5, 6, 14, and 25 decreased across
waves while the intercept of item 21 increase from T1 to
T2. Regarding residual variances, all non-equivalent
items showed decrease of residual variance except for
items 13 and 22 that showed an increase of residual vari-
ance over time. All the factor variances and covariances
are equivalent across time attesting the structural stabil-
ity of the EPIC-26 questionnaire. Factor correlation
ranged between .187 and .622 in absolute value with the
highest link between urinary incontinence and urinary
irritation. Finally, three factor means (i.e., bowel, sexual,
Table 2 Sample characteristics
Age 63.4 ± 7.12





Table 3 The distribution of item responses
T1 T2
ITEMS M SD M SD
1 2,13 1,59 3,72 1,62
2 2,75 0,76 3,30 0,68
3 1,41 1,08 0,46 0,73
4a 1,92 1,26 0,90 1,07
4b 0,62 0,94 0,10 0,38
4c 0,20 0,58 0,01 0,13
4d 0,79 1,09 0,40 0,77
4e 1,90 1,21 1,08 1,14
6a 0,42 0,79 0,28 0,63
6b 0,34 0,72 0,21 0,59
6c 0,03 0,19 0,03 0,26
6d 0,02 0,12 0,03 0,19
6e 0,75 1,00 0,28 0,62
7 1,55 0,90 1,31 0,69
8a 1,58 0,94 1,82 1,08
8b 1,87 1,19 2,28 1,27
9 1,91 1,13 2,19 1,20
10 1,91 1,33 2,15 1,36
11 1,57 0,97 1,73 1,07
12 2,81 1,39 3,02 1,46
13a 1,12 0,47 1,25 0,73
13b 1,08 0,38 1,10 0,40
13c 1,56 0,91 1,56 0,99
13d 1,90 1,08 1,54 0,94
13e 1,38 0,78 1,34 0,80
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and hormonal dysfunctions) showed to be equivalent
across waves; on the contrary, urinary incontinence and
urinary irritation decrease from the first to the second
wave.
Results of the reliability analysis attested the good in-
ternal consistency and test-retest reliability of each di-
mension (Table 5). Specifically, all Cronbach’s alphas
could be classified as minimally acceptable (i.e., above
.65) [25] except for low Cronbach’s alpha for hormonal
dysfunction at T1 and urinary irritation at both waves.
Urinary incontinence and sexual dysfunction display op-
timal reliability with values of Cronbach’s alpha above
.80 in both waves. Finally, ICCs attested the good test-
retest reliability of each dimension. Specifically, ICC for
urinary incontinence could be classified as good,
whereas the ICCs for the remaining dimensions could
be considered as moderate.
Discussion
This study represents the first attempt to assess the
validity of the Italian version of the EPIC-26. The factor
structure, longitudinal invariance and reliability of the
Italian version of the EPIC-26 were investigated in a
sample of Italian prostate cancer patients who had
undergone RARP. Results of the CFA demonstrated that
the proposed CFFM provided a good fit to data at both
waves in these patients. These results support the useful-
ness and validity of computing separate scores for each
of the five domains of urinary incontinence, urinary irri-
tation, bowel dysfunction, sexual dysfunction, and
hormonal dysfunction. The results of the reliability ana-
lyses attest the acceptable internal consistency and test-
retest reliability of most of the EPIC-26 domains. The
urinary irritation subscale is the only dimension showing
a poor internal consistency with values of Cronbach’s
alpha below the minimally acceptable cut-off at both
waves. This result is consistent with previous empirical
evidence regarding the weak reliability of this subscale in
the Chinese version of the EPIC-26 [14]. Following sug-
gestions by Lam and colleagues [14], the low reliability
of this subscale may be determined by the high propor-
tion of patients reporting no problem on the first two
items (pain on urination and bleeding with urination) of
this domain and a higher proportion of patients report-
ing moderate problems or incomplete emptying and
need to urinate frequently during the day. Another pos-
sible explanation of this low reliability is the limited
number of items in this domain compared with other
domains (urinary incontinence, sexual, bowel, and hor-
monal dysfunction). Notably, the first two items measur-
ing urinary irritation, alongside with item 2 (urinary
control), item 13 (bloody stools), item 22 (hot flashes),
and item 23 (breast tenderness) display a low factor
loading below .30. Thus, all these items could be consid-
ered weak indicators of their respective dimensions. Fur-
ther research is needed to identify more reliable
indicators of urinary irritation in patients with prostate
cancer by developing new ad-hoc items. Regarding test-
retest reliability, all dimensions displayed at least moder-
ate reliability.
Table 4 Results of the sequential process of assessing measurement invariance of the EPIC-26
Model SB Χ2 df p RMSEA CFI TLI SRMR ΔCFI
Configural Invariance 1892.249 1105 .000 .044 .913 .904 .062 –
Metric Invariance 2003.830 1125 .000 .047 .903 .895 .068 - .010
Scalar Invariance 2279.990 1145 .000 .052 .875 .866 .071 - .028
Partial Scalar Invariance - Item 14 2225.603 1144 .000 .051 .881 .872 .071 - .022
Partial Scalar Invariance – Item 5 2196.445 1143 .000 .051 .884 .876 .070 - .019
Partial Scalar Invariance – Item 25 2155.922 1142 .000 .050 .888 .880 .070 - .015
Partial Scalar Invariance – Item 6 2126.187 1141 .000 .049 .891 .883 .069 - .012
Partial Scalar Invariance – Item 21 2101.490 1140 .000 .048 .894 .886 .069 - .009
Residual Variance Invariance 2232.515 1160 .000 .051 .882 .875 .078 - .012
Partial Residual Variance Invariance – Item 13 2219.857 1159 .000 .050 .883 .876 .075 - .011
Partial Residual Variance Invariance – Item 22 2167.399 1158 .000 .049 .889 .882 .072 - .005
Factor Variance Invariance 2191.584 1163 .000 .050 .887 .881 .077 - .002
Factor Covariance Invariance 2231.046 1173 .000 .050 .883 .878 .078 - .004
Factor Mean Invariance 2562.749 1178 .000 .057 .847 .841 .098 - .036
Partial Factor Mean Invariance – Urinary Incontinence 2383.217 1177 .000 .053 .867 .862 .081 - .016
Partial Factor Mean Invariance – Urinary Irritation 2291.617 1176 .000 .051 .877 .872 .078 - .006
The best fitting model for each of the seven steps of measurement invariance assessment is indicated in bold
Note: SB Satorra-Bentler Chi Square, df degree of freedom, RMSEA Root mean square error of approximation, CFI Comparative fit index, TLI Tucker-Lewis index
(TLI), SRMR Standardized root mean square residual, ΔCFI Difference in CFI between models
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Fig. 2 Standardized parameters of the final CFFM. Note: IN = Urinary incontinence; IR = Urinary irritation; BD = Bowel dysfunction; SD = Sexual
dysfunction; HD = Hormonal dysfunction
Table 5 Cronbach’s alphas and ICC assessing internal consistency and test-retest reliability of the EPIC-26
Dimension T1 Cronbach’alpha T2 Cronbach’alpha ICC correlation (95% CI)
Urinary incontinence .886 .862 .764 (.717–.804)
Urinary irritation .585 .518 .600 (.529–.662)
Bowel dysfunction .699 .736 .536 (.458–.606)
Sexual dysfunction .860 .902 .552 (−.088–830)
Hormonal dysfunction .638 .700 .636 (.570–693)
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Testing longitudinal measurement invariance is a pre-
requisite for understanding whether changes in patients’
urinary incontinence, urinary irritation, bowel dysfunc-
tion, sexual symptomatology, and hormonal dysfunction
over time reflect true changes in quality of life or rather
changes in the psychometric properties or structure of
the EPIC-26 over time. This study also demonstrated
the good longitudinal invariance of the EPIC-26. This
self-report measure was administered to the same sam-
ple of patients with prostate cancer who had undergone
RARP in order to assess all the sequential steps of meas-
urement invariance over time. Results demonstrated a
full weak invariance of the EPIC-26 across time. Specif-
ically, its entire factor loading is invariant over time and,
thus, indicating that all of them are related to their re-
spective domains equivalently across waves. We also
demonstrated a partial strong invariance and a partial
strict invariance of the EPIC-26 over time attesting re-
spectively that the majority of the expected responses
are equivalent over time and that the amount of item
variance not accounted by the latent factor was the same
across the two waves. The non-invariant thresholds of
items 5, 6, 14, 21, and 25 suggested that patients evalu-
ate these specific symptoms differently over time. Specif-
ically, responses to these items revealed that patients
who had undergone RARP reported a significant de-
crease over time of pain or burning on urination, bleed-
ing on urination, bloody stools, and lack of energy.
Conversely, they showed a significant increase of amount
of problem related to their sexual function or the lack of
sexual function.
Finally, after the partial strict invariance, results also
attested the structural invariance of the EPIC-26 across
the two waves. We found equivalence of factor variances
and covariances over time suggesting respectively that
the same amounts of individual differences in patients’
quality of life were found between T1 and T2 and that a
strong structural stability exists among the five EPIC-26
domains over time. Moreover, the five EPIC-26 domains
showed from moderate to strong stability across time.
Finally, the results of the factor mean invariance demon-
strated that the levels of bowel, sexual, and hormonal
dysfunctions tend to be equal over time. On the other
hand, self-reported levels of urinary incontinence and ir-
ritation significantly decreased from 45 days to 6 months
after the RARP.
The large number of studies using this instrument (the
50- and 26-item versions) [10] and the high number of
language translations [12–15, 26–31] make an Italian
validation necessary. The Italian validation of the Ex-
panded Prostate Cancer Index Composite – Short Form
confirms its validity and reliability in measuring Quality
of Life in prostate cancer patients over time. Beyond its
reliability, the Short Form is easier than the longer
version of the questionnaire, reducing administration
burden with only 10 min for the compilation [10].
Limitations
One of the main limitations of this study is the lack of
other self-report measures of quality of life or patients’
well-being, which could be useful to better assess con-
vergent and/or divergent validity of the EPIC-26. How-
ever, we did not include any other measures to minimize
burden on such patients.
Moreover, the EPIC-26 was administered to patients
who had undergone RARP only; the lack of other treat-
ment types may affect the internal consistency. More
precisely, our results may show poor internal consistency
in the urinary irritation subscale because patients who
had undergone RARP did not suffer from this side
effect.
Conclusion
To sum up, the current study attests the validity and
reliability of the CFFM of the Italian version of the
EPIC-26 in patients with prostate cancer undergone
RARP. Thus, we suggest using five distinct domain
scores of urinary incontinence, urinary irritation, bowel
dysfunction, sexual symptomatology, and hormonal dys-
function on both clinical and research practice. The
EPIC-26 is demonstrated to be a valid and reliable self-
report measure of health-related quality of life for
patients with prostate cancer.
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